Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
100 hedge funds and large institutions have $465M invested in Progenics Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 6 closing their positions.
400% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 6
145% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $1M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
59% more capital invested
Capital invested by funds: $293M → $465M (+$172M)
28% more funds holding
Funds holding: 78 → 100 (+22)
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.9M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.02M |
| 3 |
RA
Royce & Associates
New York
|
+$6M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$3.31M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$8.25M |
| 2 |
Morgan Stanley
New York
|
-$2.36M |
| 3 |
FM
Forward Management
San Francisco,
California
|
-$2.3M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.59M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$886K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JG
101
Jefferies Group
New York
| – | -$389K | -75,000 | Closed |
|
|
LP
102
LMR Partners
London,
United Kingdom
| – | -$292K | -56,338 | Closed |
|
103
Jane Street
New York
| – | -$226K | -43,559 | Closed |
|
|
TDC
104
Thompson Davis & Co
Richmond,
Virginia
| – | -$26K | -5,000 | Closed |
|
105
BNP Paribas Financial Markets
Paris,
France
| – | -$20.9K | -4,023 | Closed |
|
PGNX Hedge Fund Activity: Q4 2014 in Review
100 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2014, worth a combined $465M — up 59% from $293M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PGNX positions and 6 closed out — a net gain of 24 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was State Street, adding an estimated $12.9M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $8.25M sold.
- 100 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2014, up from 78 in Q3 2014.
- Funds reported $465M of Progenics Pharmaceuticals Inc stock for Q4 2014, up 59% quarter-over-quarter.
- 30 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2014 and 6 closed out, a net change of +24 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2014 was State Street, an estimated $12.9M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2014 was Highland Capital Management (Texas), an estimated $8.25M sold.
Based on aggregated 13F filings for Q4 2014.